Avedro, a world leader in corneal collagen crosslinking (CXL) science and technology, is celebrating 10 years of research and development into the KXL Accelerated CXL system as well as its new mosaic refractive CXL system.
The company, which has pioneered accelerated crosslinking, claims that its Vibex riboflavin solutions offer safer, faster and more effective keratoconus and ectasia treatments.
Avedro’s new KXL Accelerated CXL system has a sleek, mobile design with a larger touch screen, pre-set treatment protocols, user customisable protocols and a built in patient database, which stores treatment and image data. Using Avedro’s family of high quality riboflavin formulations and established protocols, the KXL can be used to provide safe and predictable treatment for patients via epi-off, epi-on, accelerated, pulsed or continuous and LASIK Xtra treatments.
A Medicare rebate for crosslinking is now available, making this successful treatment even more affordable for patients.
the KXL can be used to provide safe and predictable treatment for patients via epi-off, epi-on, accelerated, pulsed or continuous and LASIK Xtra treatments
Contact: Designs for Vision (AUS) 02 9509 8100
